Antibodies from Multiple Sclerosis Brain Identified Epstein-Barr Virus Nuclear Antigen 1 & 2 Epitopes which Are Recognized by Oligoclonal Bands.
CNS
EBNA
Epitope
Epstein-Barr virus (EBV)
IgG antibodies
Multiple sclerosis
Oligoclonal bands
Peptides
Phage display
Journal
Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology
ISSN: 1557-1904
Titre abrégé: J Neuroimmune Pharmacol
Pays: United States
ID NLM: 101256586
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
11
05
2020
accepted:
27
07
2020
pubmed:
19
8
2020
medline:
18
1
2022
entrez:
19
8
2020
Statut:
ppublish
Résumé
Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS), the etiology of which is poorly understood. The most common laboratory abnormality associated with MS is increased intrathecal immunoglobulin G (IgG) synthesis and the presence of oligoclonal bands (OCBs) in the brain and cerebrospinal fluid (CSF). However, the major antigenic targets of these antibody responses are unknown. The risk of MS is increased after infectious mononucleosis (IM) due to EBV infection, and MS patients have higher serum titers of anti-EBV antibodies than control populations. Our goal was to identify disease-relevant epitopes of IgG antibodies in MS; to do so, we screened phage-displayed random peptide libraries (12-mer) with total IgG antibodies purified from the brain of a patient with acute MS. We identified and characterized the phage peptides for binding specificity to intrathecal IgG from patients with MS and from controls by ELISA, phage-mediated Immuno-PCR, and isoelectric focusing. We identified two phage peptides that share sequence homologies with EBV nuclear antigens 1 and 2 (EBNA1 and EBNA2), respectively. The specificity of the EBV epitopes found by panning with MS brain IgG was confirmed by ELISA and competitive inhibition assays. Using a highly sensitive phage-mediated immuno-PCR assay, we determined specific bindings of the two EBV epitopes to IgG from CSF from 46 MS and 5 inflammatory control (IC) patients. MS CSF IgG have significantly higher bindings to EBNA1 epitope than to EBNA2 epitope, whereas EBNA1 and EBNA2 did not significantly differ in binding to IC CSF IgG. Further, the EBNA1 epitope was recognized by OCBs from multiple MS CSF as shown in blotting assays with samples separated by isoelectric focusing. The EBNA1 epitope is reactive to MS intrathecal antibodies corresponding to oligoclonal bands. This reinforces the potential role of EBV in the etiology of MS. Graphical abstract Antibodies purified from an MS brain plaque were panned by phage display peptide libraries to discern potential antigens. Phage displaying peptide sequences resembling Epstein-Barr Virus Nuclear Antigens 1 & 2 (EBNA1 & 2) epitopes were identified. Antibodies from sera and CSF from other MS patients also reacted to those epitopes.
Identifiants
pubmed: 32808238
doi: 10.1007/s11481-020-09948-1
pii: 10.1007/s11481-020-09948-1
pmc: PMC7431217
doi:
Substances chimiques
Antibodies, Viral
0
Epitopes
0
Epstein-Barr Virus Nuclear Antigens
0
Oligoclonal Bands
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
567-580Subventions
Organisme : NIMH NIH HHS
ID : R21 MH118174
Pays : United States
Informations de copyright
© 2020. Springer Science+Business Media, LLC, part of Springer Nature.
Références
J Clin Invest. 2005 May;115(5):1352-60
pubmed: 15841210
Nat Commun. 2017 Apr 21;8:15072
pubmed: 28429719
Immunol Lett. 2020 Jan;217:15-24
pubmed: 31689443
Rev Med Virol. 2006 Sep-Oct;16(5):297-310
pubmed: 16927411
J Virol Methods. 1997 Nov;68(2):119-25
pubmed: 9389401
Autoimmunity. 1999;30(3):131-42
pubmed: 10520896
Expert Rev Neurother. 2013 Mar;13(3):287-97
pubmed: 23448218
J Virol. 2004 May;78(10):5194-204
pubmed: 15113901
Jundishapur J Microbiol. 2015 Jun 27;8(6):e15985
pubmed: 26322199
Neurology. 2004 Jun 22;62(12):2277-82
pubmed: 15210894
J Immunol. 1998 Apr 1;160(7):3315-21
pubmed: 9531289
J Exp Med. 2008 Aug 4;205(8):1763-73
pubmed: 18663124
J Virol. 1995 Jun;69(6):3752-8
pubmed: 7745723
Neurology. 1992 Sep;42(9):1798-804
pubmed: 1381067
J Neuroimmunol. 2006 Mar;172(1-2):121-31
pubmed: 16371235
JAMA. 2005 May 25;293(20):2496-500
pubmed: 15914750
Mol Cell Proteomics. 2016 Apr;15(4):1360-80
pubmed: 26831522
Mult Scler. 2012 May;18(5):605-9
pubmed: 22020417
Genome Med. 2019 Apr 30;11(1):26
pubmed: 31039804
Ann Neurol. 2010 Feb;67(2):159-69
pubmed: 20225269
Proteins. 2006 Oct 1;65(1):40-8
pubmed: 16894596
JAMA. 2001 Dec 26;286(24):3083-8
pubmed: 11754673
Mult Scler. 2013 Nov;19(13):1694-5
pubmed: 24218488
Front Oncol. 2019 Aug 06;9:713
pubmed: 31448229
J Virol. 2007 Sep;81(18):10092-100
pubmed: 17626071
Lancet. 2008 Oct 25;372(9648):1502-17
pubmed: 18970977
Genes Immun. 2012 Jan;13(1):14-20
pubmed: 21776012
PLoS One. 2020 Feb 21;15(2):e0228883
pubmed: 32084151
PLoS One. 2012;7(9):e45152
pubmed: 22984622
J Immunol. 1999 Jan 1;162(1):129-35
pubmed: 9886378
J Virol. 2007 Jul;81(13):6777-84
pubmed: 17459939
J Immunol Methods. 2006 Oct 20;316(1-2):67-74
pubmed: 17010370
Mult Scler Relat Disord. 2017 Aug;16:24-30
pubmed: 28755681
Lancet. 1981 Dec 5;2(8258):1290
pubmed: 6118702
Nucleic Acids Res. 2016 Jul 8;44(W1):W449-54
pubmed: 27131374
Clin Transl Immunology. 2017 Jan 20;6(1):e126
pubmed: 28197337
J Neuroimmunol. 2010 Aug 25;225(1-2):149-52
pubmed: 20510468
J Virol. 1999 Jul;73(7):5795-802
pubmed: 10364331
J Virol. 2002 Mar;76(5):2480-90
pubmed: 11836426
CNS Neurol Disord Drug Targets. 2012 Aug;11(5):556-69
pubmed: 22583440
J Neuroimmunol. 2011 Dec 15;240-241:129-36
pubmed: 22079192
Arch Neurol. 2006 Jun;63(6):839-44
pubmed: 16606758
Nucleic Acids Res. 2017 Jul 3;45(W1):W24-W29
pubmed: 28472356
PLoS One. 2015 Apr 08;10(4):e0119605
pubmed: 25853421
Mult Scler. 2016 Mar;22(3):279-91
pubmed: 26041797
Mult Scler. 2013 Nov;19(13):1692-3
pubmed: 24218487
Mult Scler. 2012 Sep;18(9):1204-8
pubmed: 22685062
J Neurol Neurosurg Psychiatry. 2009 May;80(5):498-505
pubmed: 19015225
Neurology. 2015 Mar 31;84(13):1362-8
pubmed: 25740864
Mult Scler Relat Disord. 2017 Aug;16:8-14
pubmed: 28755684
J Neuroimmunol. 2011 Apr;233(1-2):192-203
pubmed: 21176973
J Neurol Neurosurg Psychiatry. 1998 Jul;65(1):48-55
pubmed: 9667560
Neurology. 2008 Sep 23;71(13):1033-5
pubmed: 18809840
Virology. 1999 Sep 30;262(2):321-32
pubmed: 10502511
Neurology. 2009 Jul 7;73(1):32-8
pubmed: 19458321
J Neuroimmunol. 2014 May 15;270(1-2):51-5
pubmed: 24642384
Mult Scler. 2010 Mar;16(3):355-8
pubmed: 20203149
Chin J Cancer. 2014 Dec;33(12):609-19
pubmed: 25418195
Cold Spring Harb Perspect Med. 2019 Apr 1;9(4):
pubmed: 29735578
J Virol. 1994 Nov;68(11):7374-85
pubmed: 7933121
Mult Scler. 2013 Nov;19(13):1690-1
pubmed: 24218486
PLoS One. 2013 Apr 09;8(4):e61110
pubmed: 23585874
N Engl J Med. 2000 Aug 17;343(7):481-92
pubmed: 10944566
PLoS One. 2017 Oct 23;12(10):e0186842
pubmed: 29059249
Proc Natl Acad Sci U S A. 2019 Aug 20;116(34):16955-16960
pubmed: 31375628
Mult Scler. 2007 Apr;13(3):420-3
pubmed: 17439912
Brain. 2006 Jun;129(Pt 6):1493-506
pubmed: 16569670
J Virol. 2006 Dec;80(24):12121-30
pubmed: 17130301
Eur J Neurol. 2016 Jan;23(1):140-7
pubmed: 26453465
J Immunol Methods. 2007 Sep 30;326(1-2):33-40
pubmed: 17669417
J Neurol Neurosurg Psychiatry. 2011 Oct;82(10):1142-8
pubmed: 21836034
FEBS Lett. 1990 Dec 10;276(1-2):172-4
pubmed: 1702393
JAMA. 2004 Apr 21;291(15):1875-9
pubmed: 15100207
J Neurol Sci. 2000 Feb 1;173(1):32-9
pubmed: 10675577
Ann Neurol. 2006 Mar;59(3):499-503
pubmed: 16502434
Brain Res. 2015 Sep 16;1620:17-28
pubmed: 25998538